Literature DB >> 1473123

Clinical and virological aspects of HIV2 infection in rhesus monkeys.

J Livartowski1, D Dormont, F Boussin, S Chamaret, D Guetard, R Vazeux, P Lebon, H Metivier, L Montagnier.   

Abstract

To establish an animal model of AIDS, two different "wild" or "adapted" HIV2 Rod and Eho strains were cultivated on monkey cells from different species (baboons, cynomolgus, Rhesus monkeys). Five different available strains were then injected both by intravenous (i.v.) and intracerebral (i.c.) route into ten Rhesus monkeys. Seven animals seroconverted between days 13 and 230. Reverse transcriptase activity in the lymphocyte culture supernatants was detectable in six of the seven animals that seroconverted, and in one animal that remained seronegative. Lymphopenia and a decrease in the CD4+ cell counts were observed in eight animals. One animal, inoculated with HIV2-Rod "wild type," developed a severe cachexia, with dyspnea, and associated neurological symptoms 150 days after inoculation. This animal was sacrificed on day 220. Pathological examination showed typical lesions of actinomycetes infection in the lungs and in the meninges. Another monkey had significant weight loss associated with lymphadenopathies and pancytopenia. These results suggest that in vivo replication of HIV2 in Rhesus monkeys may induce clinical symptoms of immune deficiency. This method is reproducible and may provide a good model for AIDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473123

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  2 in total

1.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

2.  Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques.

Authors:  M H Bäyon-Auboyer; F D Boussin; G Vogt; R Le Grand; B Vaslin; I Nicol-Jourdain; D Dormont
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.